Sustaining Innovation Analyst Day

Dupixent® FDA approval call

Sanofi and Regeneron hosted a conference call & webcast following the approval of Dupixent® for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease.

The presentation was followed by a Q&A session.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies